Filtered By:
Condition: Hemorrhagic Stroke
Therapy: Stem Cell Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 98 results found since Jan 2013.

Neurorestorative Responses to Delayed Human Mesenchymal Stromal Cells Treatment of Stroke in Type 2 Diabetic Rats Basic Sciences
Conclusions—In T2DM stroke rats, delayed hMSC treatment significantly improves neurological functional outcome and increases neurorestorative effects and M2 macrophage polarization. Increasing brain platelet-derived growth factor expression may contribute to hMSC-induced neurorestoration.
Source: Stroke - October 23, 2016 Category: Neurology Authors: Yan, T., Venkat, P., Chopp, M., Zacharek, A., Ning, R., Roberts, C., Zhang, Y., Lu, M., Chen, J. Tags: Cell Therapy, Stem Cells, Diabetes, Type 2, Cerebrovascular Disease/Stroke, Ischemic Stroke Original Contributions Source Type: research

Human Neural Stem Cell Extracellular Vesicles Improve Recovery in a Porcine Model of Ischemic Stroke Basic Sciences
Conclusions—This study demonstrated for the first time that in a large animal model novel NSC EVs significantly improved neural tissue preservation and functional levels post-MCAO, suggesting NSC EVs may be a paradigm changing stroke therapeutic.
Source: Stroke - April 23, 2018 Category: Neurology Authors: Robin L. Webb, Erin E. Kaiser, Brian J. Jurgielewicz, Samantha Spellicy, Shelley L. Scoville, Tyler A. Thompson, Raymond L. Swetenburg, David C. Hess, Franklin D. West, Steven L. Stice Tags: Animal Models of Human Disease, Basic Science Research, Translational Studies, Treatment, Ischemic Stroke Original Contributions Source Type: research

Involvement of T-bet and GATA3 transcription factors in Mesenchymal stem cells and royal jelly combination treatment in brain stroke
Stroke as a common non-communicable disease can manifest itself as ischemic (87%) and hemorrhagic.1 However, the viable cells surrounding the infarct core have been shown to be at risk for infarct and apoptosis. Some therapeutic approaches are trying to improve neuronal recovery in the region and reduce post-stroke disability.2,3 Currently, to dissolve the clot and rescue the surrounding cells in the ischemic condition, tissue plasminogen activator (tPA) is administrated within the first three hours of the onset of stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - July 24, 2022 Category: Neurology Authors: Mohammad Kazemi Arababadi, Mohammad Reza Rahmani, Fatemeh Asadi, Ahmad Shabanizadeh, Aliakbar Yousefi-Ahmadipour Source Type: research

Cell-Based Therapies for Stroke: Promising Solution or Dead End? Mesenchymal Stem Cells and Comorbidities in Preclinical Stroke Research
Conclusion The high prevalence of comorbidities in patients with stroke indicates the need for therapies in preclinical studies that take into account these comorbidities in order to avoid failures in translation to the patient. Preclinical studies are beginning to evaluate the efficacy of MSC treatment in stroke associated with comorbidities, especially hypertension, for ischemic and hemorrhagic stroke. Regarding aging and diabetes, only ischemic stroke studies have been performed. For the moment, few studies have been performed and contradictory results are being reported. These contradictory results may be due to the u...
Source: Frontiers in Neurology - April 8, 2019 Category: Neurology Source Type: research

Effect of Inflammation on the Process of Stroke Rehabilitation and Poststroke Depression
Conclusions Stroke comprises ischemic stroke and ICH. The immuno-inflammatory process is involved in neural plasticity following events such as a hemorrhage or ischemic stroke. After ischemia, astrocytes, microglia, and MDMs play important roles during rehabilitation with the modulation of cytokines or chemokines, such as TNF-α and IL-1. Moreover, MiRNAs are also important posttranscriptional regulators in these glial mitochondrial responses to cerebral ischemia. ICH involves processes similar and different to those seen in ischemia, including neuronal injury, astrocytic and microglial/macrophage activation, and n...
Source: Frontiers in Psychiatry - April 10, 2019 Category: Psychiatry Source Type: research

Combining Human Umbilical Cord Blood Cells With Erythropoietin Enhances Angiogenesis/Neurogenesis and Behavioral Recovery After Stroke
In conclusion, our results suggest that hUCBC infusion in combination with EPO administration demonstrates therapeutic efficacy in the treatment of stroke-induced injury by promoting neurogenesis and angiogenesis. Further research that delineates the therapeutic mechanism of systemically administered hUCBC and EPO is required. Ethics Statement All experimental procedures involving animals were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U. S. National Institutes of Health and were approved by CHA University Institutional Animal Care & Use Com...
Source: Frontiers in Neurology - April 9, 2019 Category: Neurology Source Type: research

Using Dental Pulp Stem Cells for Stroke Therapy
Conclusion and Future Perspectives Stem cell-based therapy is a promising alternative for stroke treatment. While stem cells from different sources, including induced PSC, ESC, MSC, and NSC, have been investigated, using NSC and enhancing the natural mechanisms is most appropriate for brain repair. In preclinical models of stroke, stem cell transplantation has led to positive outcomes through a variety of cellular and molecular mechanisms, many being mediated by the array of beneficial factors produced by the cells. Recent advances in cellular reprogramming have provided alternative sources of NSC to be investigated, allo...
Source: Frontiers in Neurology - April 28, 2019 Category: Neurology Source Type: research

Stem cell stroke treatment trial results 'show promise'
This study looked at the safety and tolerability of a stem cell therapy called ReN001 in the treatment of ischaemic stroke, where the blood supply to the brain is blocked by a blood clot. The findings, which were reported in a press release, suggest that the nine people included in the study experienced no adverse effects and showed a modest improvement in stroke-related symptoms. However, the full findings from the PISCES trial are yet to be published in a peer-reviewed journal. Until this happens, it is worth exercising a little healthy scepticism about the claims being made. This research is still at a very early s...
Source: NHS News Feed - May 28, 2013 Category: Consumer Health News Tags: Neurology Medical practice QA articles Source Type: news

'Safe' stem cell therapy may help stroke recovery
Conclusion This study provides evidence that a new technique using a patient's own stem cells to aid the recovery from severe ischaemic stoke is feasible and appears to be safe. It was not designed to test whether the technique was better than doing nothing or better than other types of care or treatment. The authors are perfectly clear that this "proof-of-concept study was not designed with a control group or powered to be able to detect efficacy". This means we cannot be sure that the improvements seen in the five patients were caused by the stem cell treatment. They could have occurred anyway as part of the na...
Source: NHS News Feed - August 11, 2014 Category: Consumer Health News Tags: Genetics/stem cells Heart/lungs Source Type: news

Predictive Risk Factors of In-Hospital Mortality Following Acute Stroke in the United States: Data from the Nationwide Inpatient Database, 2006-2010 (P02.015)
CONCLUSIONS: The rate of in-hospital mortality is relatively high following acute stroke (8.42%). We identified multiple risk factors of in-hospital mortality in acute stroke patients. The strongest risk factor is the type stroke (hemorrhagic). The present finding suggests that patients at increased risk of mortality can be identified and additional treatment for prevention might be warranted.Disclosure: Dr. Naderi has nothing to disclose. Dr. Abcede has nothing to disclose. Dr. Al-Khoury has nothing to disclose. Dr. Mozaffar has received personal compensation for activities with California Stem Cell Inc., NuFactor, Cresce...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Naderi, N., Abcede, H., Al-Khoury, L., Mozaffar, T., Jain, V. Tags: P02 Cerebrovascular Disease II Source Type: research

Human placenta mesenchymal stem cell protection in ischemic stroke is Angiotensin converting enzyme ‐2 (ACE‐2) and masR receptor dependent
In this study we demonstrated that hPMSC-derived ACE2 is required to protect against progressive loss of cerebral blood perfusion following ischemic stroke. This effect is also mediated through vascular endothelial Mas receptor but not AT2 receptor. Consequently, the results of our experimental stroke studies with human derived stem cells describes new paracrine function of hPMSC in which ACE2 and Mas receptor are critical, therefore, providing a novel therapeutic strategy for stroke in near future.
Source: Stem Cells - June 15, 2021 Category: Stem Cells Authors: Mansoureh Barzegar, Shantel Vital, Karen Y. Stokes, Yuping Wang, J. Winny Yun, Luke A. White, Oleg Chernyshev, Roger E. Kelley, Jonathan S. Alexander Tags: Regenerative Medicine Source Type: research

Clinical Outcomes of Repeated Intraventricular Transplantation of Autologous Bone Marrow Mesenchymal Stem Cells in Chronic Haemorrhagic Stroke. A One-Year Follow Up.
Conclusion: Intraventricular transplantation of BM-MSCs has shown benefits in improving the functional status of post-haemorrhagic stroke patients with no adverse effect. PMID: 29290837 [PubMed]
Source: The Open Neurology Journal - January 3, 2018 Category: Neurology Tags: Open Neurol J Source Type: research

Treatments in Ischemic Stroke: Current and Future
Background and Aim: Despite progress made over the last 30 years, stroke is still a leading cause of disability and mortality; likewise, its burden is expected to increase over the next decades, due to population growth and aging. The development of drugs with better safety-efficacy profiles as well as strategies able to improve ischemic stroke management from the pre-hospital setting is needed.Summary: The pathophysiology of ischemic stroke involves multiple pathways resulting in cerebral artery obstruction and brain tissue ischemia. To date, the only approved drug for acute ischemic stroke is intravenous thrombolytic alt...
Source: European Neurology - August 2, 2022 Category: Neurology Source Type: research

Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke.
CONCLUSIONS: There are significant safety concerns regarding EPO therapy for stroke. It is too early to know whether other CSFs improve functional outcome. PMID: 23797623 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - June 24, 2013 Category: Journals (General) Authors: Bath PM, Sprigg N, England T Tags: Cochrane Database Syst Rev Source Type: research

Neuroprotective effect of a cell-free extract derived from human adipose stem cells in experimental stroke models.
Abstract A recent study suggested that a cell-free extract of human adipose stem cells (hASCs-E) has beneficial effects on neurological diseases by modulating the host environment. Here, we investigated the effects of an hASCs-E in several experimental models of stroke in vitro (oxygen and glucose deprivation, OGD) and in vivo (transient or permanent focal cerebral ischemia and intracerebral hemorrhage, ICH). Ischemia was induced in vitro in Neuro2A cells, and the hASCs-E was applied 24 hour before the OGD or concurrently. Focal cerebral ischemia was induced by unilateral intraluminal thread occlusion of the middl...
Source: Neurobiology of Disease - January 30, 2013 Category: Neurology Authors: Jeon D, Chu K, Lee ST, Jung KH, Ban JJ, Park DK, Yoon HJ, Jung S, Yang H, Kim BS, Choi JY, Kim SH, Kim JM, Won CH, Kim M, Lee SK, Roh JK Tags: Neurobiol Dis Source Type: research